326 related articles for article (PubMed ID: 36999962)
1. Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.
Chen F; Wang Y; Chen X; Yang N; Li L
Ann Med; 2023 Dec; 55(1):1156-1170. PubMed ID: 36999962
[No Abstract] [Full Text] [Related]
2. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
Front Immunol; 2021; 12():569287. PubMed ID: 33841390
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
5. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
6. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Karakioulaki M; Eyerich K; Patsatsi A
Am J Clin Dermatol; 2024 Mar; 25(2):195-212. PubMed ID: 38157140
[TBL] [Abstract][Full Text] [Related]
7. The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.
Messingham KN; Crowe TP; Fairley JA
Front Immunol; 2019; 10():2331. PubMed ID: 31636640
[TBL] [Abstract][Full Text] [Related]
8. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance.
Tukaj S; Bieber K; Prüßmann W; Prüßmann JN; Schmidt E; Zillikens D; Ludwig RJ; Kasperkiewicz M
Arch Dermatol Res; 2023 Dec; 315(10):2921-2926. PubMed ID: 35960354
[TBL] [Abstract][Full Text] [Related]
10. Eosinophils as putative therapeutic targets in bullous pemphigoid.
Simon D; Borradori L; Simon HU
Exp Dermatol; 2017 Dec; 26(12):1187-1192. PubMed ID: 28833620
[TBL] [Abstract][Full Text] [Related]
11. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
12. Eosinophils in bullous pemphigoid.
Jones VA; Patel PM; Amber KT
Panminerva Med; 2021 Sep; 63(3):368-378. PubMed ID: 32536149
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
14. IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients.
Lamberts A; Kotnik N; Diercks GFH; Meijer JM; Di Zenzo G; Pas HH; Jonkman MF; Gibbs BF; Raap U; Horváth B
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):973-980. PubMed ID: 33058320
[TBL] [Abstract][Full Text] [Related]
15. Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid.
Limberg MM; Weihrauch T; Gray N; Ernst N; Hartmann K; Raap U
Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509055
[TBL] [Abstract][Full Text] [Related]
16. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
Messingham KN; Pietras TA; Fairley JA
G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
[TBL] [Abstract][Full Text] [Related]
17. FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid.
Messingham KN; Srikantha R; DeGueme AM; Fairley JA
J Immunol; 2011 Jul; 187(1):553-60. PubMed ID: 21646296
[TBL] [Abstract][Full Text] [Related]
18. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
[TBL] [Abstract][Full Text] [Related]
20. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
